Furnish Price to Retailer and Moving Annual Turnover value in respect of 11 Formulations: NPPA

Published On 2022-12-02 12:30 GMT | Update On 2023-10-19 09:28 GMT

New Delhi: Taking an appropriate action for fixation of the ceiling prices pursuant to the issue of Revised Schedule-I of DPCO, 2013, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, the Government of India, has released an office memorandum requesting all the manufacturing and marketing companies to furnish the Price to Retailer (PTR) and Moving...

New Delhi: Taking an appropriate action for fixation of the ceiling prices pursuant to the issue of Revised Schedule-I of DPCO, 2013, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, the Government of India, has released an office memorandum requesting all the manufacturing and marketing companies to furnish the Price to Retailer (PTR) and Moving Annual Turnover (MAT) in value terms for the month of July 2022, in respect of 11 formulations with different dosages.

The list of 11 formulations includes Bedaquiline, Bendamustinehydrochloride, Buprenorphine, Buprenorphine (A) plusNaloxone (B), Daclatasvir, Delamanid, Irinotecan HCltrihydrate, Phenoxymethyl penicillin, ProcaineBenzylpenicillin, TenofovirDisproxilFumarate(A) plus Lamivudine(B)+Dolutegravir(c), Valganciclovir.

Earlier, the Medical Dialogue Team had reported the upgradation of the National List of Essential Medicines (NLEM) 2022, comprising 384 drugs across 27 therapeutic categories.

In accordance with the revised National List of Essential Medicines, the 34 new medicines were added to the list which includes Amikacin, Bedaquiline, Bendamustine Hydrochloride, Buprenorphine, Buprenorphine (A) plus Naloxone (B), Cefuroxime, Dabigatran, Daclatasvir, Darunavir (A) plus Ritonavir (B), Delamanid, Dolutegravir, Fludrocortisone, Insulin Glargine, Irinotecan HCI Trihydrate, Itraconazole, Ivermectin, Lamivudine, Latanoprost, Lenalidomide, Leuprolide acetate, Meropenem, Montelukast, Mupirocin, Nicotine replacement therapy (NRT), Ormeloxifene (Centchroman), Phenoxymethyl penicillin,Procaine Benzyl penicillin, Rotavirus vaccine, Tenecteplase,Teneligliptin, Tenofovir (A) + Lamivudine (B) + Dolutegravir (C), Tenofovir Alafenamide Fumarate (TAF), Terbinafine, Valganciclovir.

Also Read:Union Health Ministry Releases NLEM 2022, 34 Drugs Added, 26 Removed

Recently, with reference to the fixation of ceiling prices for scheduled formulations under Revised Schedule I (NLEM 2022) of DPCO 2013, the NPPA asked all the concerned manufacturers / marketing companies to furnish the Price to Retailer (PTR) and Moving Annual Turnover (MAT) in value terms for the month of July, 2022 in the format mentioned given in Table 1.

Table 1

S.No.	Formulation	Brand	Composition & Strength	Dosage/Specification		Price to Retailer (PTR) for July, 2022	MAT* Sales Value as on July, 2022 (Rs.)
S.No.	Formulation	Brand	Composition & Strength	Type	Size	Price to Retailer (PTR) for July, 2022	MAT* Sales Value as on July, 2022 (Rs.)
1.
2.
3.
4.

"*Moving Annual Turnover (MAT) Sales (excluding taxes) for July 2022 means total sales during August 2021 to July 2022." it is added.

Furthermore, the office memorandum added, "The information may be furnished positively within 7 days from the Issue of this O.M. in respect of formulations mentioned in Table 2 below for taking appropriate action for fixation of ceiling prices pursuant to the issue of Revised Schedule-I of DPCO, 2013."

Table 2

S.N.	NLEM, 2022 Section No.	Medicine	Dosage form(s) and strength(s)
1	6.4.2	Bedaquiline	Tablet100mg
2	7.1.6	Bendamustinehydrochlorid e	Injection 25 mg/ vial
3	23.5.1	Buprenorphine	Tablet(Sub-lingual)0.4mg
4	23.5.2	Buprenorphine (A) +Naloxone (B)	Tablet(Sub-lingual)0.4mg(A)+0.1mg(B)
5	23.5.2	Buprenorphine (A) +Naloxone (B)	Tablet(Sub-lingual)2mg(A)+0.5mg(B)
6	6.8.1	Daclatasvir	Tablet30mg
7	6.4.6	Delamanid	Tablet50mg
8	7.1.26	Irinotecan HCltrihydrate	Solutionforinjection20mg/mL
9	6.2.2.11	Phenoxymethyl penicillin	Tablet250mg
10	6.2.2.12	ProcaineBenzylpenicillin	Powder for injection1000mg(=1millionIU)
11	6.7.1.6	TenofovirDisproxilFumarate (A) +Lamivudine(B)+Dolutegra vir(c)	Tablet300mg(A)+300mg(B)+50 mg(c)
12	6.6.2.1	Valganciclovir*	Powder for oral solution 50mg / mL

"The above-mentioned information may be furnished within the stipulated period so that the ceiling prices are fixed in a transparent manner." the O.M further added.

Also Read:NPPA Panel Fixes Retail Price Of Sachet containing Pantoprazole 40mg marketed by Alkem

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Furnish Price to Retailer and Moving Annual Turnover value in respect of 11 Formulations: NPPA

Similar News